LumiraDx Launches Rapid Onsite COVID-19 Surveillance Test for Simultaneous Testing of Five Samples on Portable Instrument

LumiraDx (London, UK) has announced the US launch of its COVID-19 Surveillance Test, for environments such as schools and workplaces.

The LumiraDx SARS-CoV-2 Ag Surveillance Test allows simultaneous testing of up to five samples on a small, portable instrument with cost per sample as low as USD 4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using an affordable, easy-to-use, onsite testing platform. LumiraDx's announcement comes at a time when schools across the US are assessing how to both bring students back to in-person learning while also monitoring for outbreaks to ensure they can stay safe and open.


The LumiraDx SARS-CoV-2 Ag Surveillance Test, used on the LumiraDx Platform, has demonstrated 100.0% positive agreement and 96.6% negative agreement with its comparator, the LumiraDx SARS-CoV-2 Ag Test. It allows rapid, high-sensitivity surveillance testing in both CLIA and non-CLIA certified settings. The company also offers the LumiraDx SARS-CoV-2 Ag Test and SARS-CoV-2 Ab Test for clinical use in CLIA waived settings on the LumiraDx Platform, both of which were granted Emergency Use Authorization by the FDA.

“Our rapid onsite COVID-19 Surveillance Test offers options that can fit into a variety of different use-cases to support a safe return to school or the workplace and instill confidence in groups about their environment,” said Pooja Pathak, LumiraDx Chief Product Officer. “By pooling up to five samples at one time, the LumiraDx SARS-CoV-2 Ag Surveillance test provides an efficient, accurate and cost-effective way to implement a surveillance testing program.”

Related Links:
LumiraDx